DRG TM-CA 72-4 ELISA Kit used in NYU Winthrop Hospital Cancer Study!

Jul 26, 2017 | Events | 0 comments

Dr. Cyril E. Geacintov

DRG is proud to announce that our TM-CA 72-4 ELISA Kit (EIA-5071) has been used in a recent cancer study done by NYU Winthrop Hospital. The DRG TM-CA 72-4 ELISA Kit is for sale in the United States as an RUO product and is CE marked for global sales. Please see details on the study below, as well as a link to the article. See an excerpt from the article abstract below:

“Cancer antigen CA72-4 is a tumor marker found to be elevated in a variety of human adenocarcinomas. Using the DRG TM-CA72-4, [researchers] quantified the elevation of CA72-4 compared to current United States Food And Drug Administration-approved tumor markers in various cancer types.

Materials and Methods: We conducted a prospective, single-center study enrolling 96 patients between March 2013 and August 2016 with different locally advanced, unresectable or metastatic cancer known to express CA72-4. Quantification of CA72-4 was performed according to the manufacturer’s instructions using the DRG TM-CA72-4 enzyme-linked immunosorbent assay kit and the positivity rates were calculated.

Results: CA72-4 expression varied with tumoral site of origin, with the highest positivity rates found in pancreatic and ovarian malignancies. Correlation with clinical activity was also noted in some patients.

Conclusion: CA72-4 may have a potential role as an adjunct to conventional biomarkers in disease monitoring of pancreatic, ovarian and colorectal carcinomas.”

If you are interested in purchasing or finding more information on DRG’s TM-CA 72-4 ELISA Kit (EIA-5071) you can find a link to it here in our new Ecommerce store: https://store.drg-international.com/shop/tm-ca-72-4-elisa.asp

You can also call +1-973-564-7555 or email [email protected] for more information.


The article is used by permission from the International Institute of Anticancer Research (IIAR).

The article original source publication is: Anticancer Research, Vol. 37, No. 7, pp. 3649-3656.

Links below:

http://ar.iiarjournals.org/content/37/7/3649 (abstract only)

http://ar.iiarjournals.org/content/37/7/3649.long (full article)

http://ar.iiarjournals.org/content/37/7/3649.full.pdf (pdf version)

Gregory C. Guest

Gregory C. Guest

Gregory C. Guest is the International Marketing Manager located at DRG International’s worldwide headquarters in Springfield, NJ.
Gregory C. Guest

News and Updates

Sign Up for Our Newsletter

  • By submitting this form, you are granting: DRG International, Inc., 841 Mountain Avenue, Springfield, NJ, 07081, permission to email you. You may unsubscribe via the link found at the bottom of every email. (See our Email Privacy Policy (http://constantcontact.com/legal/privacy-statement) for details.) Emails are serviced by Constant Contact.

Click the link to learn more about how DRG is certified in the manufacturing and distribution of in-vitro diagnostic reagents used in the diagnosis of autoimmune status, cancer, cardiac markers, disease status, fertility testing, pregnancy testing, diabetes and immune status.